Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 221

1.

HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.

Gusenbauer S, Vlaicu P, Ullrich A.

Oncogene. 2013 Aug 15;32(33):3846-56. doi: 10.1038/onc.2012.396. Epub 2012 Oct 8.

PMID:
23045285
[PubMed - indexed for MEDLINE]
2.

Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.

Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S.

Clin Cancer Res. 2012 Mar 15;18(6):1663-71. doi: 10.1158/1078-0432.CCR-11-1171. Epub 2012 Feb 8.

PMID:
22317763
[PubMed - indexed for MEDLINE]
Free Article
3.

Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.

Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S.

Clin Cancer Res. 2010 Jan 1;16(1):174-83. doi: 10.1158/1078-0432.CCR-09-1204. Epub 2009 Dec 15.

PMID:
20008840
[PubMed - indexed for MEDLINE]
Free Article
4.

TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.

Okamoto W, Okamoto I, Tanaka K, Hatashita E, Yamada Y, Kuwata K, Yamaguchi H, Arao T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.

Mol Cancer Ther. 2010 Oct;9(10):2785-92. doi: 10.1158/1535-7163.MCT-10-0481. Epub 2010 Aug 17.

PMID:
20716641
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.

Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S.

Clin Cancer Res. 2011 Apr 15;17(8):2260-9. doi: 10.1158/1078-0432.CCR-10-1993. Epub 2011 Jan 10.

PMID:
21220474
[PubMed - indexed for MEDLINE]
Free Article
6.

Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.

Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S, Yano S.

Clin Cancer Res. 2009 Nov 1;15(21):6630-8. doi: 10.1158/1078-0432.CCR-09-1001. Epub 2009 Oct 20.

PMID:
19843665
[PubMed - indexed for MEDLINE]
Free Article
7.

Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.

Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S.

Am J Pathol. 2012 Sep;181(3):1034-43. doi: 10.1016/j.ajpath.2012.05.023. Epub 2012 Jul 9.

PMID:
22789825
[PubMed - indexed for MEDLINE]
8.

Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.

Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.

Mol Cancer Ther. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Epub 2012 Jul 25.

PMID:
22844075
[PubMed - indexed for MEDLINE]
Free Article
9.

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

Nguyen KS, Kobayashi S, Costa DB.

Clin Lung Cancer. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039. Review.

PMID:
19632948
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.

Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Lee SS, Kim CH, Yoo YD, Lee JC.

Mol Cancer Res. 2009 Oct;7(10):1736-43. doi: 10.1158/1541-7786.MCR-08-0504. Epub 2009 Oct 6.

PMID:
19808904
[PubMed - indexed for MEDLINE]
Free Article
11.

Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.

Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K, Yano S.

J Thorac Oncol. 2012 Feb;7(2):272-80. doi: 10.1097/JTO.0b013e3182398e69.

PMID:
22089117
[PubMed - indexed for MEDLINE]
12.

The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.

Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Nakamura T, Matsumoto K, Yano S.

Int J Cancer. 2013 Jul 15;133(2):505-13. doi: 10.1002/ijc.28034. Epub 2013 Feb 12.

PMID:
23319394
[PubMed - indexed for MEDLINE]
13.

Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.

Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Yano S.

J Thorac Oncol. 2012 Jul;7(7):1078-85. doi: 10.1097/JTO.0b013e3182519a2c.

PMID:
22592212
[PubMed - indexed for MEDLINE]
14.

Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.

Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.

BMC Med. 2012 Mar 21;10:28. doi: 10.1186/1741-7015-10-28.

PMID:
22436374
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells.

Bonine-Summers AR, Aakre ME, Brown KA, Arteaga CL, Pietenpol JA, Moses HL, Cheng N.

Cancer Biol Ther. 2007 Apr;6(4):561-70.

PMID:
17495520
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).

Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R.

Int J Mol Med. 2007 Jul;20(1):3-10. Review.

PMID:
17549382
[PubMed - indexed for MEDLINE]
17.

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S.

Cancer Res. 2008 Nov 15;68(22):9479-87. doi: 10.1158/0008-5472.CAN-08-1643.

PMID:
19010923
[PubMed - indexed for MEDLINE]
Free Article
18.

Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors.

Filosto S, Becker CR, Goldkorn T.

Mol Cancer Ther. 2012 Apr;11(4):795-804. doi: 10.1158/1535-7163.MCT-11-0698. Epub 2012 Feb 1.

PMID:
22302097
[PubMed - indexed for MEDLINE]
Free Article
19.

The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.

Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A.

Mol Cancer Res. 2010 Aug;8(8):1142-51. doi: 10.1158/1541-7786.MCR-09-0388. Epub 2010 Jul 20.

PMID:
20647329
[PubMed - indexed for MEDLINE]
Free Article
20.

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S.

PLoS Med. 2007 Oct;4(10):1669-79; discussion 1680.

PMID:
17973572
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk